InnoCan Pharma Corporation (CSE: INNO)

Market Cap	47.87M
Revenue (ttm)	39.08M
Net Income (ttm)	-3.52M
Shares Out	290.12M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,850
Average Volume	27,694
Open	0.180
Previous Close	0.180
Day's Range	0.165 - 0.180
52-Week Range	0.160 - 0.330
Beta	2.93
RSI	36.99
Earnings Date	Mar 31, 2025

About InnoCan Pharma

InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments, Pharmaceuticals and Consumer Wellness. It engages in the research and development of CBD loaded exosomes, as well as operates LPT CBD-loaded liposome platform that facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream f...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2018
• Country: Canada
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: INNO

Financial Performance

In 2023, InnoCan Pharma's revenue was $13.66 million, an increase of 433.69% compared to the previous year's $2.56 million. Losses were -$4.70 million, 24.9% more than in 2022.

Financial numbers in USD